For any queries, please contact Customer Services or your Account Manager. Dismiss
News & Analysis (3)
-
May 06, 2025 | Comment In patent clash with Xarelto-maker Bayer, Mylan’s PTAB win called into question
...potential problem with the Patent Trial and Appeal Board’s claim construction of Bayer’s US Patent No. 10,828,310...
Sections: Intellectual Property
-
May 05, 2025 | Insight Conflation of dosing regimen with efficacy at issue in Bayer appeal in US
...approval to make generic rivaroxaban, Bayer filed several lawsuits asserting infringement of US Patent No. 10,828,310...
Sections: Intellectual Property
-
January 22, 2024 | Official Statement Bayer AG says US Patent Trial and Appeal Board wrongly cancelled Xarelto patent
...Aktiengesellschaft is seeking to undo findings by the US Patent Trial and Appeal Board that its US Patent No. 10,828,310...
Sections: Intellectual Property
Get the inside track, with MLex
With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
TRY MLEX FREE FOR 14 DAYS
Already a subscriber? Click here to login